DSO-5a manufacturers
- DSO-5a
-
- $2500.00
-
2026-07-27
- CAS:2195411-63-1
- Purity:
- Supply Ability: 10g
|
| Product Name: | DSO-5a | | Synonyms: | DSO-5a;2-Furancarboxylic acid, 1-[(5E,8E)-5,8-dihydro-5,8-bis(hydroxyimino)-1,4-dimethoxy-2-naphthalenyl]-2,2-dimethyl-3-buten-1-yl ester | | CAS: | 2195411-63-1 | | MF: | C23H24N2O7 | | MW: | 440.45 | | EINECS: | | | Product Categories: | | | Mol File: | 2195411-63-1.mol |  |
| | DSO-5a Chemical Properties |
| Melting point | 240-242 °C | | Boiling point | 632.254±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.276±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 9.997±0.20(predicted) |
| | DSO-5a Usage And Synthesis |
| Uses | DSO-5a is a potent, selective, orally active BB3 agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates ppar-γ activity through BB3 and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research[1]. | | in vivo | DSO-5a (3-30 mg/kg; P.O.; 30 min) reduces blood glucose excursions in a dose-dependent manner in C57BL/6 mice[1].
DSO-5a (10 mg/kg/day; P.O.; 2-4 weeks) reduces the blood glucose concentration of diabetic db/db mice[1].
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 3 mg/kg; 10 mg/kg; 30 mg/kg | | Administration: | Oral administration;30 min before glucose challenge (3 g/kg) | | Result: | Showed that the change rates of AUC at 3, 10 and 30 mg/kg were 5.03, 16.42 and 28.30%, respectively.
In BB3 knockout mice, DSO-5a failed to inhibit blood glucose drift. |
| Animal Model: | Diabetic db/db mice[1] | | Dosage: | 10 mg/kg/day | | Administration: | Oral administration; 2-4 weeks | | Result: | After two weeks of treatment, the blood glucose excursion of db/db mice was significantly reduced.
After four weeks, fasting blood glucose levels, glycosylated serum protein (GSP), and HOMA-IR were significantly decreased in the DSO-5a treatment group.
Increased the protein expression of PPAR-gamma in white adipose tissue of db/db mice.
|
| | IC 50 | PPARγ | | References | [1] Wu L, et al. Discovery of Dimethyl Shikonin Oxime 5a, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Type 2 Diabetes Mellitus. J Med Chem. 2023 Jun 22;66(12):8011-8029. DOI:10.1021/acs.jmedchem.3c00323 |
| | DSO-5a Preparation Products And Raw materials |
|